Conversion to Dysport in Cervical Dystonia Patients
Status:
Not yet recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
The first line of therapy for cervical dystonia patients is botulinum toxin injections,
however injection parameter determination and optimization are challenging for physicians to
do. In addition, some patients receiving this treatment long-term experience short duration
of relief. Thus, Dysport (Ipsen Biopharmaceuticals), another BoNT-A formulation, may increase
the duration of clinical benefit. The objective of this study is to compare the wearing off
time of their original BoNT-A formulation (same injection parameters for at least 3 cycles)
and the optimized treatment of Dysport (after 2 injection cycles). Ideally, the clinical
benefits should last 2.5 - 3 months as injections are administered every 3 months. Conversion
to Dysport will be conducted and optimization of Dysport dosing will be done using our
sensor-technology assessment.